Abstract: Compositions containing purified collagen biomaterial derived from tissues, for example, insoluble amnion, soluble amnion, soluble chorion of the human placenta, are provided. The collagen compositions can be used to promote wound healing, promote tissue regeneration, prevent or reduce scarring, reduce local inflammation, minimize tissue rejection, promote graft integration. Methods for using the collagen composition as a biomaterial implant for dermal filling, skin grafting, and hair transplantation are also provided.

Abstract: Compositions containing purified collagen biomaterial derived from tissues, for example, insoluble amnion, soluble amnion, soluble chorion of the human placenta, are provided. The collagen compositions can be used to promote wound healing, promote tissue regeneration, prevent or reduce scarring, reduce local inflammation, minimize tissue rejection, promote graft integration. Methods for using the collagen composition as a biomaterial implant for dermal filling, skin grafting, and hair transplantation are also provided.

Abstract: Compositions containing purified collagen biomaterial derived from tissues, for example, insoluble amnion, soluble amnion, soluble chorion of the human placenta, are provided. The collagen compositions can be used to promote wound healing, promote tissue regeneration, prevent or reduce scarring, reduce local inflammation, minimize tissue rejection, promote graft integration. Methods for using the collagen composition as a biomaterial implant for dermal filling, skin grafting, and hair transplantation are also provided.

Abstract: Methods of preventing and treating cancer, and of suppressing the growth or proliferation of cancer, using the amniotic fluid-derived d-MAPPS™ regenerative biologics platform technology (“d-MAPPS”). The d-MAPPS compositions contain significant numbers of placental tissue-derived mesenchymal stem cells, growth factors, anti-inflammatory cytokines, and are amenable for long-term storage without the loss of biological potency. In certain embodiments, d-MAPPS is shown to improve survival of tumor bearing animals. In other embodiments, d-MAPPS is used in combination with, or formulated with, one or more additional active agents.

Abstract: A human amniotic fluid formulation has been developed for topical application to the eye, which is useful for the treatment of ocular diseases and injuries including dry eyes, Sjogren's Syndrome, cataracts, burns and injuries to the eye tissues. The formulation is a sterile de-cellularized human amniotic fluid (D-HAF), devoid of amniotic stem cells and elements of micronized membrane or chorion particles. Methods for treating, or preventing various ocular diseases, injuries and disorders using the formulation, optionally in combination with one or more therapeutic, prophylactic or diagnostic agents are described.

Abstract: Disclosed herein are compositions, formulations, and/or methods of using mesenchymal stem cells (MSCs) for preventing and treating cancer, and for suppressing the growth or proliferation of cancer. The MSCs contain significant numbers of anti-tumor compounds, including, for instance, growth factors, anti-inflammatory cytokines, and the like, and are amenable for long-term storage without the loss of biological potency. In at least one embodiment, various types of MSCs are shown to improve survival of tumor bearing animals. In at least another embodiment, one or more types of MSCs are used in combination with, or formulated with, one or more additional active agents.

Abstract: A human amniotic fluid formulation has been developed for topical application to the eye, which is useful for the treatment of ocular diseases and injuries including dry eyes, Sjogren's Syndrome, cataracts, burns and injuries to the eye tissues. The formulation is a sterile de-cellularized human amniotic fluid (D-HAF), devoid of amniotic stem cells and elements of micronized membrane or chorion particles. Methods for treating, or preventing various ocular diseases, injuries and disorders using the formulation, optionally in combination with one or more therapeutic, prophylactic or diagnostic agents are described.

Abstract: Compositions containing purified collagen biomaterial derived from tissues, for example, insoluble amnion, soluble amnion, soluble chorion of the human placenta, are provided. The collagen compositions can be used to promote wound healing, promote tissue regeneration, prevent or reduce scarring, reduce local inflammation, minimize tissue rejection, promote graft integration. Methods for using the collagen composition as a biomaterial implant for dermal filling, skin grafting, and hair transplantation are also provided.

Abstract: Provided herein is a pre-Caesarean method for collecting amniotic fluid from a patient. A needle is inserted into the incision site for the future C-section, which may be under ultrasound guidance, through which the amniotic fluid is drawn under a low level suction and, optionally, gravity to a sterile collection container. The method encompasses filtering and/or irradiating the amniotic fluid to collect biomolecules of interest such as growth factors and/or stem cells. Also provided is the sterile amniotic fluid or filtrates thereof collected by the method described herein.

Abstract: Formulations of human amniotic fluid and methods of use thereof for treatment of chronic lung disorders have been developed. The formulations are suitable for topical delivery to the lung, for treatment of lung disorders including chronic obstructive pulmonary disorders (COPD), asthma, emphysema, bronchiectasis, chronic bronchitis, interstitial lung disease, alpha-I antitrypsin emphysema. Methods including administering specifically formulated, diluted sterile decellularized human amniotic fluids topically to the lungs, preferably as aerosol droplets, are described. In particular the methods involving administration of the amniotic fluid formulation in the form of aerosol droplets with size between about 1.5 ?m to about 5 ?m, preferably from about 2.5 ?m to about 3.5 ?m, inclusive, using apparatus such as high-efficiency vibrating mesh nebulizers, are described.

Abstract: Formulations of human amniotic fluid and methods of use thereof for treatment of lung disorders, and/or injuries have been developed. The formulations are suitable for topical delivery to the lung for treatment of lung disorders including chronic obstructive pulmonary disorders (COPD), asthma, emphysema, bronchiectasis, chronic bronchitis, interstitial lung disease, alpha-1 antitrypsin emphysema, as well as for treatment of acute lung injuries. Methods including administering specifically formulated, diluted sterile de-cellularized human amniotic fluids topically to the lungs, preferably as aerosol droplets, are described. In particular, the methods involving administration of the amniotic fluid formulation in the form of aerosol droplets with size between about 1.5 ?m to about 5 ?m, preferably from about 2.5 ?m to about 3.5 ?m, inclusive, using apparatus such as high-efficiency vibrating mesh nebulizers, are described.

Abstract: A human amniotic fluid formulation has been developed for administration into a joint or associated soft tissue such as a tendon or ligament for treatment of pain, degeneration, or injury. The formulation is a sterile de-cellularized human amniotic fluid (D-HAF), devoid of amniotic stem cells and elements of micronized membrane or chorion particles, which has not been heat treated or treated with ethidium bromide. The formulation is optionally diluted, or concentrated, depending on the severity of the disorder or injury. Examples demonstrate efficacy in treatment of pain, disease, disorder, degeneration or injury of a joint or associated soft tissues.

Abstract: A human amniotic fluid formulation has been developed for administration into a joint or associated soft tissue such as a tendon or ligament for treatment of pain, degeneration or injury. The formulation is a sterile de-cellularized human amniotic fluid (D-HAF), devoid of amniotic stem cells and elements of micronized membrane or chorion particles, which has not been heat treated or treated with ethidium bromide. The formulation is optionally diluted, or concentrated, depending on he severity of the disorder or injury. Examples demonstrate efficacy in treatment of pain, disease, disorder, degeneration or injury of a joint or associated soft.

Abstract: Compositions and formulations of de-cellularized human amniotic fluid (D-HAF) and methods of use thereof are described. The compositions and formulations typically including over 300 human growth factors and stem cell derived exosomes can be used for therapeutic immunosuppression strategies useful in the treatment of inflammatory diseases or disorders, autoimmune diseases or disorders, inducing or increase graft tolerance, treating graft rejection, and treating allergies and other ailments particularly those involving eyes, joints, and the respiratory system with symptoms that can be reduced or ameliorated by regulating the activity of T cells (Th1, Th2, Th17, and/or Tregs), NK cells, antigen-presenting cells, or combinations thereof. Compositions and methods for balancing a T-helper cell profile and in particular for suppressing or reducing expansion of inflammatory Th1 and Th17 cells and/or promoting generation of immunosuppressive Tregs are provided.

Abstract: Provided herein is a pre-Caesarean method for collecting amniotic fluid from a patient. A needle is inserted into the incision site for the future C-section, which may be under ultrasound guidance, through which the amniotic fluid is drawn under a low level suction and, optionally, gravity to a sterile collection container. The method encompasses filtering and/or irradiating the amniotic fluid to collect biomolecules of interest such as growth factors and/or stem cells.

Abstract: Provided herein is a topical wound dressing that comprises a collagen and a flexible paste. Also provided is a wound dressing with a first layer of a sterilized mixture of collagen and a second adhesive layer effective to adhere to surrounding skin and to keep the first layer in contact with the wound. In addition there is provided a wound dressing foil that comprises collagen and a plastic compound that can provide a foil shape. Furthermore, methods of dressing wounds utilizing the wound dressings and wound dressing foil are provided herein.

Abstract: Provided herein is a pre-Caesarean method for collecting amniotic fluid from a patient. A needle is inserted into the incision site for the future C-section, which may be under ultrasound guidance, through which the amniotic fluid is drawn under a low level suction and, optionally, gravity to a sterile collection container. The method encompasses filtering and/or irradiating the amniotic fluid to collect biomolecules of interest such as growth factors and/or stem cells. Also provided is the sterile amniotic fluid or filtrates thereof collected by the method described herein.

Abstract: Provided herein is a method for sterilely filtering amniotic fluid from selected caesarean sections of an individual. The amniotic fluid is first centrifuged at 5,000 to 10,000 rpm for 30 to 60 minutes and filtered through filters with about 5 to about 10 ?m pore size. Next, the fluid is sequentially filtered through a series of membrane filters with the pore sizes 1 ?m and 0.45 or/and 0.2 ?m. The filtrate is then aseptically transferred to and sealed in syringes or vials. The fluid is subsequently lyophilized to obtain the lyophilisate of amniotic fluid. Amniotic fluid is reconstituted by adding sterile water to the lyophilisate, and the reconstituted fluid is used for wound healing, cosmetic, orthopedic or ophthalmic applications, particularly for the treatment of dry eyes.

Abstract: Compositions containing purified collagen biomaterial derived from tissues, for example, insoluble amnion, soluble amnion, soluble chorion of the human placenta, are provided. The collagen compositions can be used to promote wound healing, promote tissue regeneration, prevent or reduce scarring, reduce local inflammation, minimize tissue rejection, promote graft integration. Methods for using the collagen composition as a biomaterial implant for dermal filling, skin grafting, and hair transplantation are also provided.

Abstract: A human amniotic fluid formulation has been developed for topical application to the eye, which is useful for the treatment of ocular diseases and injuries including dry eyes, Sjogren's Syndrome, cataracts, burns and injuries to the eye tissues. The formulation is a sterile de-cellularized human amniotic fluid (D-HAF), devoid of amniotic stem cells and elements of micronized membrane or chorion particles. Methods for treating, or preventing various ocular diseases, injuries and disorders using the formulation, optionally in combination with one or more therapeutic, prophylactic or diagnostic agents are described.